Collectively, targeting the immune checkpoint complex CD47-SIRPα has been shown as a promising anti-tumor strategy that may remodel the GBM microenvironment, restore innate and adaptive immunity functions, and improve the prognosis of patients with GBM. The gene discussed is CD47; the disease is glioblastoma.